Audentes Therapeutics, Inc. - FORM S-1/A - EX-23.1 - CONSENT OF KPMG LLP - June 16, 2016

Attached files

file filename
EX-10.10B - NET COMMERCIAL LEASE BY AND BETWEEN THE REGISTRANT AND JCN PARTNERS - Audentes Therapeutics, Inc.d892618dex1010b.htm
S-1/A - AMENDMENT NO. 2 TO FORM S-1 - Audentes Therapeutics, Inc.d892618ds1a.htm
EX-10.19 - FIRST AMENDMENT TO LICENSE AGREEMENT NO. A13169 - Audentes Therapeutics, Inc.d892618dex1019.htm
EX-10.18 - EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT - Audentes Therapeutics, Inc.d892618dex1018.htm
EX-10.9 - SUBLEASE BY AND BETWEEN THE REGISTRANT AND SOLAZYME, INC. - Audentes Therapeutics, Inc.d892618dex109.htm

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

The Board of Directors

Audentes Therapeutics, Inc.:

We consent to the use of our report included herein and to the reference to our firm under the heading “Experts” in the prospectus.

/s/ KPMG LLP

San Francisco, California

June 16, 2016

Audentes Therapeutics, Inc. Reports